Idelalisib Trial Stopped Because of 'Overwhelming Efficacy'Idelalisib Trial Stopped Because of 'Overwhelming Efficacy'

In chronic lymphocytic leukemia, idelalisib combined with bendamustine and rituximab improved progression-free and overall survival compared with the standard two-drug combination. Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Related Links:

Authors: Bright SA, Byrne AJ, Vandenberghe E, Browne PV, Mcelligott AM, Meegan MJ, Williams DC Abstract The nitrostyrene scaffold was previously identified as a lead target structure for the development of effective compounds targeting Burkitt's lymphoma. The present study aimed to develop these compounds further in haematological malignancies, including chronic lymphocytic leukaemia (CLL). Cellular viability, flow cytometry and lactate dehydrogenase assays, amongst others, were used to examine the effects of nitrostyrene compounds on CLL cells, including a cell line representing disease with poor prognosis (HG‑3...
Source: Oncology Reports - Category: Cancer & Oncology Tags: Oncol Rep Source Type: research
Chronic lymphocytic leukemia (CLL) patients who achieve undetectable minimal residual disease (U-MRD) (i.e.,
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research
Conditions:   Refractory Chronic Lymphocytic Leukemia;   Refractory Small Lymphocytic Lymphoma Interventions:   Drug: Trabectedin;   Drug: Venetoclax Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
In this study, we describe a case of “eosinophilic eruption of myeloproliferative disease” associated with diffuse large B-cell lymphoma in a young adult. To the best of our knowledge, this is the first case reported in association with diffuse large B-cell lymphoma.
Source: The American Journal of Dermatopathology - Category: Pathology Tags: Extraordinary Case Report Source Type: research
Low molecular weight protein tyrosine phosphatase (LMW-PTP) is overexpressed in different cancer types and its expression is related to more aggressive disease, reduced survival rate and drug resistance. Morin...
Source: Cancer Cell International - Category: Cancer & Oncology Authors: Tags: Primary research Source Type: research
Chronic lymphocytic leukemia (CLL) therapy has changed dramatically with the introduction of several targeted therapeutics. Ibrutinib was the first approved for use in 2014 and now is used for initial and salvage therapy of CLL patients. With its widespread use in clinical practice, ibrutinib’s common and uncommon adverse events reported less frequently in earlier clinical trials have been experienced more frequently in real-world practice. In particular, atrial fibrillation, bleeding, infections, and arthralgias have been reported. The management of ibrutinib’s adverse events often cannot be generalized but mu...
Source: Blood - Category: Hematology Authors: Tags: How I Treat, Free Research Articles, Lymphoid Neoplasia, Clinical Trials and Observations Source Type: research
At this meeting there will be special emphasis on the theoretical and practical aspects of IGHV gene mutational analysis in clinical diagnostics with a focus on next generation sequencing, data interpretation and reporting. There will also be two hands-on practical sessions (basic and advanced) where participants will have the opportunity to get practical guidance and training on Ig sequence interpretation in CLL by experts in this field.Air date: 3/29/2019 9:00:00 AM
Source: Videocast - All Events - Category: General Medicine Tags: Upcoming Events Source Type: video
This event is based on the experience of six educational workshops previously organized by the ERIC in Europe and it will be first such workshop taking place in the US. At this meeting there will be special emphasis on the theoretical and practical aspects of IGHV gene mutational analysis in clinical diagnostics with a focus on next generation sequencing, data interpretation and reporting. There will also be two hands-on practical sessions (basic and advanced) where participants will have the opportunity to get practical guidance and training on Ig sequence interpretation in CLL by experts in this field.Air date: 3/27/2019 9:00:00 AM
Source: Videocast - All Events - Category: General Medicine Tags: Upcoming Events Source Type: video
Condition:   Chronic Lymphocytic Leukemia Intervention:   Sponsor:   Brno University Hospital Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
AbstractThe antigen-mediated triggering of B cell receptor (BCR) activates the transcription factor NF- κB that regulates the expression of genes involved in B cell differentiation, proliferation, and survival. The tyrosine kinase Btk is essentially required for the activation of NF-κB in BCR signaling through the canonical pathway of IKK-dependent phosphorylation and proteasomal degradation of IκB -α, the main repressor of NF-κB. Here, we provide the evidence of an additional mechanism of NF-κB activation in BCR signaling that is Btk-dependent and IKK-independent. In DeFew B lymphoma ce...
Source: Journal of Molecular Medicine - Category: Molecular Biology Source Type: research
More News: Cancer & Oncology | Chronic Leukemia | Chronic Lymphocytic Leukemia | Health | Hematology | Leukemia | Rituxan | Treanda